Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII

Thrombosis Research

Volumn 134, Issue 1, 2014, Pages 125-131

  Zollner, Sabine ^a   Raquet, Elmar ^b   Claar, Philipp ^b   Müller Cohrs, Jochen ^b   Metzner, Hubert J ^b   Weimer, Thomas ^b   Pragst, Ingo ^b   Dickneite, Gerhard ^b   Schulte, Stefan ^b  

^a ZLB Behring AG   (Switzerland)

^b CSL BEHRING GMBH   (Germany)

Author keywords

Animal models; Coagulation factors; Haemophilia A B; Haemophilia therapy; von Willebrand factor

Indexed keywords

ANTIGEN; CSL 627; FERRIC CHLORIDE; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8; RECOMBINANT FACTOR VIII SQ;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTERY OCCLUSION; ARTICLE; ASSAY; BINDING AFFINITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; EX VIVO STUDY; FEMALE; HEMOPHILIA A; HEMOSTASIS; IN VIVO STUDY; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RABBIT; RAT; SINGLE DRUG DOSE; SURFACE PLASMON RESONANCE; ANIMAL; DISEASE MODEL; METABOLISM;

ANIMALS; DISEASE MODELS, ANIMAL; FACTOR VIII; HEMOPHILIA A; MACACA FASCICULARIS; MICE; RABBITS; RATS; SURFACE PLASMON RESONANCE; VON WILLEBRAND FACTOR;

EID: 84902547350     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.03.028     Document Type: Article

References (34)

1. K. Fijnvandraat, W.S. Bril, and J. Voorberg Immunobiology of inhibitor development in hemophilia A Semin Thromb Hemost 29 2003 61 68
2. J. Klinge, N.M. Ananyeva, C.A. Hauser, and E.L. Saenko Hemophilia A-from basic science to clinical practice Semin Thromb Hemost 28 2002 309 322
3. P. Lollar Molecular characterization of the immune response to factor VIII Vox Sang 83 Suppl. 1 2002 403 408
4. J. Astermark, J. Voorberg, H. Lenk, D. DiMichele, A. Shapiro, and G. Tjonnfjord et al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro Haemophilia 9 2003 567 572
5. A. Gringeri, L.G. Mantovani, L. Scalone, and P.M. Mannucci Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group Blood 102 2003 2358 2363
6. S. Bjorkman, A. Folkesson, and S. Jonsson Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A Eur J Clin Pharmacol 65 2009 989 998
7. P.J. Lenting, C.J. Van Schooten, and C.V. Denis Clearance mechanisms of von Willebrand factor and factor VIII J Thromb Haemost 5 2007 1353 1360
8. S. Dasgupta, Y. Repesse, J. Bayry, A.M. Navarrete, B. Wootla, and S. Delignat et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors Blood 109 2007 610 612
9. E.L. Saenko, and N.M. Ananyeva Receptor-mediated clearance of factor VIII: implications for pharmacokinetic studies in individuals with haemophilia Haemophilia 12 2006 15 22
10. E.G. Tuddenham, R.S. Lane, F. Rotblat, A.J. Johnson, T.J. Snape, and S. Middleton et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease Br J Haematol 52 1982 259 267
11. S.V. Kaveri, S. Dasgupta, S. Andre, A.M. Navarrete, Y. Repesse, and B. Wootla et al. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells Haemophilia 13 Suppl. 5 2007 61 64
12. S. Lacroix-Desmazes, A.M. Navarrete, S. Andre, J. Bayry, S.V. Kaveri, and S. Dasgupta Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A Blood 112 2008 240 249
13. S. Delignat, Y. Repesse, A.M. Navarrete, Y. Meslier, N. Gupta, and O.D. Christophe et al. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A Haemophilia 18 2012 248 254
14. S. Schulte Pioneering designs for recombinant coagulation factors Thromb Res 128 Suppl. 1 2011 S9 S12
15. S. Schmidbauer, R. Witzel, J. Kreuter, T. Weimer, H. Metzner, and C. Horn et al. Physico-chemical characterization of recombinant single chain FVIII Hämostaseologie 32 2012 A41 [P2-29]
16. S. Schmidbauer, R. Witzel, J. Kreuter, S. Schwingal, L. Robbel, and P. Sebastian et al. Characterization of recombinant single chain FVIII, rVIII-SingleChain (CSL627) Haemophilia 18 Suppl. 3 2012 37
17. G.A. Vehar, B. Keyt, D. Eaton, H. Rodriguez, D.P. O'Brien, and F. Rotblat et al. Structure of human factor VIII Nature 312 1984 337 342
18. Y. Sawamoto, R. Prescott, D. Zhong, E.L. Saenko, E. Mauser-Bunschoten, and K. Peerlinck et al. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors Thromb Haemost 79 1998 62 68
19. H. Wakabayashi, A.E. Griffiths, and P.J. Fay Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations J Thromb Haemost 7 2009 438 444
20. S. Zollner, E. Raquet, A. Feussner, J. Mueller-Cohrs, H. Metzner, and T. Weimer et al. Preclinical pharmacokinetic characteristics of rVIII-SingleChain (CSL627), a novel recombinant single-chain FVIII Haemophilia 18 Suppl. 3 2012 40 [PO-TU-070]
21. S.B. Zollner, E. Raquet, J. Mueller-Cohrs, H. Metzner, T. Weimer, and I. Pragst et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII Thromb Res 132 2013 280 287
22. ® EU Summary of product characteristics 2014. Available at: http://www.emaeuropaeu/docs/en-GB/document-library/EPAR-Product- Information/human/000520/WC500022467.pdf
23. L. Bi, A.M. Lawler, S.E. Antonarakis, K.A. High, J.D. Gearhart, and H.H. Kazazian Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A Nat Genet 10 1995 119 121
24. C. Denis, N. Methia, P.S. Frenette, H. Rayburn, M. Ullman-Cullere, and R.O. Hynes et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis Proc Natl Acad Sci U S A 95 1998 9524 9529
25. H. Sandberg, C. Kannicht, P. Stenlund, M. Dadaian, U. Oswaldsson, and C. Cordula et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII Thromb Res 130 2012 808 817
26. M.L. Christiansen, K.W. Balling, E. Persson, I. Hilden, A. Bagger-Sorensen, and B.B. Sorensen et al. Functional characteristics of N8, a new recombinant FVIII Haemophilia 16 2010 878 887
27. J.A. Dumont, T. Liu, S.C. Low, X. Zhang, G. Kamphaus, and P. Sakorafas et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs Blood 119 2012 3024 3030
28. B. Mei, C. Pan, H. Jiang, H. Tjandra, J. Strauss, and Y. Chen et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment Blood 116 2010 270 279
29. H.R. Stennicke, M. Kjalke, D.M. Karpf, K.W. Balling, P.B. Johansen, and T. Elm et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models Blood 121 2013 2108 2116
30. G. Höbarth, S. Kubik, M. Wolfsegger, J.P. Lawo, A. Weber, and H. Gritsch et al. Pharmacokinetics of Baxter's longer acting rFVIII (BAX 855) in factor VIII ko mice, rats and cynomolgus monkeys Hämostaseologie 32 2012 A42 [P2-32]
31. L. Hansen, M. Ezban, O. Henrik, C. Nichols, H. Agerso, and M. Tranholm Recombinant glycopegylated FIX (40 K PEG-rFIX) demonstrates prolonged half-life in several animal species Haemophilia 16 Suppl. 4 2010 79 [17P71]
32. K. Terao, K. Fujimoto, F. Cho, and S. Honjo Inheritance and distribution of human-type A-B-O blood groups in cynomolgus monkeys J Med Primatol 10 1981 72 80U
33. M. Hoffman Animal models of bleeding and tissue repair Haemophilia 14 Suppl. 3 2008 62 67
34. B. Baumgartner, T. Jaki, M.J. Wolfsegger, B. Eder, A. Schiviz, and H.P. Schwarz et al. Optimization, refinement and reduction of murine in vivo experiments to assess therapeutic approaches for haemophilia A Lab Anim 44 2010 211 217